Faculty

David Delgado, MD

David Delgado, MD

Assistant Professor of Pediatrics

Phone: 317-944-8784
Email: dcdelgad@iu.edu
Address:
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202

Bio

Specialty

Pediatric Stem Cell Transplant

Areas of Interest

I am interested in studying novel agents to prevent graft-vs-host disease (GVHD), a common complication of donor stem cell transplant. 

Bio

I have interest and experience treating and caring for children with any condition that requires stem cell transplant including cancer, immune deficiency, metabolic disorders, aplastic anemia, HLH, sickle cell disease, Beta-thalassemia major, and other conditions.  I am also very interested and involved with translation and clinical research involving pediatric stem cell transplant patients.

Education

1998 BS DePaul University
2002 MD University of Illinois College of Medicine

Clinical

Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
317-944-2143 phone
317-944-3107 fax


Research & Grants

I am the principal investigator (PI) for a Phase I study that is using bortezomib, in addition to cyclosporine and methotrexate, to prevent GVHD.  GVHD is a common complication after donor stem cell transplant that can cause significant morbidity and mortality.  This novel treatment protocol is only open to Riley patients.  The goal is to determine the dose that is safe to use with these other two agents to eventually pursue a larger-scale trial that could potentially be open at multiple institutions.  We are grateful that Millennium is providing funding for bortezomib and the correlative studies for this trial. 


Publications

http://www-ncbi-nlm-nih-gov.proxy.medlib.iupui.edu/pubmed/?term=delgado+david+KIR

1. Delgado D, Webster DE, DeSantes KB, Durkin ET, Shaaban AF. KIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells. Pediatr Blood Cancer. 2010 Dec 15; 55(7): 1300-05.

2. Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma Receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1; 70(23): 9554-61.